Analytical Data
-
Gene name
METTL11A
-
简介
The METTL11A protein methylates the N-terminus of target proteins, specifically catalyzing monomethylation, dimethylation, or trimethylation of exposed α-amino groups in the [Ala/Gly/Ser]-Pro-Lys motif. METTL11A Protein, Human (GST) is the recombinant human-derived METTL11A protein, expressed by E. coli , with N-GST labeled tag.
- Application
-
Alternative Names
N-terminal Xaa-Pro-Lys N-methyltransferase 1; NTM1A; NTMT1; C9orf32; METTL11A; NRMT; NRMT1
-
Species
Human
-
Source
E. coli
-
Tag
N-GST
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9BV86-1
-
Expression Region
T2-R223
-
Protein Length
Partial
-
Molecular Weight
52.2 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
METTL11A, or methyltransferase-like 11A, is a member of the METTL family of RNA methyltransferases that has garnered significant attention in recent years due to its critical role in post-transcriptional regulation of gene expression. Research has indicated that METTL11A is involved in the methylation of certain RNA molecules, which can influence mRNA stability, splicing, and translation. Dysregulation of METTL11A has been linked to various diseases, including cancer, highlighting its potential as a biomarker and therapeutic target. Understanding the biochemical mechanisms and functional consequences of METTL11A's actions is crucial for elucidating its physiological roles and the impact of its dysregulation in pathological states. Recent studies employing techniques like CRISPR/Cas9 gene editing and mass spectrometry have begun to elucidate its substrate specificity and molecular pathways. Furthermore, the recombinant expression of METTL11A in vitro allows for detailed investigation of its enzymatic activity and interaction with RNA and other protein partners. These insights pave the way for exploring METTL11A's potential in therapeutic interventions and its broader implications in RNA biology.
